PEDIATRICS Vol. 90 No. 1 July 1992, pp. 144-148
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gershon, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gershon, A. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Varicella Vaccine: Still at the Crossroads

Anne A. Gershon MD1

1 From the Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, NY

Dr Saul Krugman was and continues to be a teacher, mentor, and inspiration to many in the field of infectious diseases, particularly with regard to viral infections and immunizations. It is therefore a great privilege to play a role in celebrating his 80th birthday, and it also seems appropriate to honor him with a presentation concerning live attenuated varicella vaccine. Dr Krugman was greatly responsible for bringing about clinical trials with varicella vaccine in the United States, and in fact, without his input it is unlikely that this vaccine would ever have been tested here. His recognition, in the 1950s, of the potential severity of varicella in adults was a landmark paper in the realization that varicella is not always a benign disease and is worth preventing.1 The conventional wisdom, however, has been that there was no need for a varicella vaccine because the disease is too mild to warrant immunization. There are, nevertheless, numerous well-recognized complications of varicella. The most common is bacterial superinfection which may be local and mild but on occasion may be systemic and even fatal (such as staphylococcal pneumonia). In 1984, Preblud and his colleagues2 estimated that each year in the United States, as the result of chickenpox, 56 otherwise healthy children die, 46 develop encephalitis, more than a quarter of a million children visit a physician, and physicians write a similar number of prescriptions for antipruritics and antibiotics. Moreover, children at high risk to develop severe or chronic forms of chickenpox, such as leukemics, those who have had organ transplants, and those with human immunodeficiency virus infection, are often denied such activities as attending school and social functions for fear of an unrecognized exposure to varicella.

Submitted on January 21, 1992
Accepted on March 10, 1992


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch Fam MedHome page
L. L. MacFarlane, M. L. Sanders, and P. J. Carek
Concerns Regarding Universal Varicella Immunization: Time Will Tell
Arch Fam Med, November 1, 1997; 6(6): 537 - 541.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
J. G. Donahue, P. W. Choo, J. E. Manson, and R. Platt
The Incidence of Herpes Zoster
Arch Intern Med, August 7, 1995; 155(15): 1605 - 1609.
[Abstract] [PDF]